Table 2 Treatment effects in the health economic model

Simple analgesics (tablets per month)^a

10.10

4.58

5.53 (-0.10–11.15)

[21.60]

54.7%

0.054

59

30 | 26

Antiemetic tablets (tablets per month)

2.69

0.90

1.80 (0.82–2.77)

[3.74]

66.7%

0.000

59

26 | 14

Antiemetic injections (injections per month)

0

0.02

+ 0.02 (-0.05–0.02)

[0.130]

-

0.322

59

0 | 1

Treo (tablets per month)^b

7.25

3.75

3.51 (0.90–6.11)

[10.00]

48.4%

0.001

59

25 | 25

Triptan tablets (tablets per month)

7.64

4.15

3.49 (2.21–4.78)

[4.94]

45.7%

0.000

59

40 | 38

Triptan melt tablets (melt tablets per month)

1.81

0.76

1.05 (-0.03–2.13)

[4.15]

57.9%

0.057

59

10 | 11

Triptan nose spray (uses per month)

0.31

0.31

0 (-0.34–0.34)

[1.30]

0%

1.000

59

2 | 3

Triptan injections (injections per month)

0.02

0.02

0 (-0.05–0.05)

[0.19]

0%

1.000

59

1 | 1

Beta-blockers (tablets per month)

10.42

1.61

8.81 (3.30–14.33)

[21.16]

85.6%

0.002

59

14 | 6

Antihypertensive (other than beta-blockers, tablets per month)

15.58

7.41

8.17 (3.08–13.26)

[19.53]

52.4%

0.002

59

24 | 12

Botulinum toxin (treatment cycles per month)

0.32

0.10

0.22 (0.01–0.43)

[0.81]

68.8%

0.041

59

17 | 3

Anti-depressants (tablets per month)

9.73

5.66

4.07 (-0.81–9.95)

[22.56]

41.8%

0.171

59

14 | 8

Anti-epileptics (tablets per month)

13.44

2.63

10.81 (4.88–16.75)

[22.77]

80.5%

0.000

59

17 | 3

GP visits (visits per year)

2.57

1.76

0.81 (0.13–1.49)

[2.57]

32.7%

0.020

58

37 | 26

Specialist visits (visits per year)

1.97

1.12

0.85 (0.17–1.53)

[2.61]

43.1%

0.015

59

31 | 20

Outpatient visits (visits per year)

4.07

3.51

0.56 (-1.41–2.53)

[7.56]

13.8%

0.572

59

43 | 54

ER visits (visits per year)

0.59

0.25

0.34 (0.05–0.63)

[1.09]

57.1%

0.020

59

11 | 6

Cost of hospitalisation^c (cost of hospitalisation per year)

5,780

801

4,979 (1,141–8,816)

[14,725]

13.9%

0.012

59

14 | 3